developed cisplatin‐loaded Fe3O4/Gd2O3 hybrid NPs with conjugation with lactoferrin (Lf) and RGD dimer (RGD2) (FeGd‐NH@Pt@LF/RGD2) for dual‐targeting delivery to brain tumor (Figure 6A).[152] FeGd‐NH@Pt@LF/RGD2 NPs was able to target BBB through Lf‐TfR interaction and further target brain tumor cells through RGD2‐integrin αvβ3 interaction. This evidence concerns the gene TFRC and brain neoplasm.